Filing Details

Accession Number:
0001127602-22-027870
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-19 16:45:25
Reporting Period:
2022-12-15
Accepted Time:
2022-12-19 16:45:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
882796 Biocryst Pharmaceuticals Inc BCRX Biological Products, (No Disgnostic Substances) (2836) 621413174
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1800060 L Michael Jones 4505 Emperor Blvd.
Suite 200
Durham NC 27703
Exec. Director, Finance - Pao No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-12-15 445 $10.90 10,753 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 1,462 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  2. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.54 to $11.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.